Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IBI 3003

Next Previous
X
Search
Drug Profile

IBI 3003

Alternative Names: IBI-3003

Latest Information Update: 16 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Innovent Biologics
  • Class Antineoplastics; Immunotherapies; Trispecific antibodies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Multiple myeloma

Most Recent Events

  • 12 Jun 2024 Phase-I/II clinical trials in Multiple myeloma (Second-line therapy or greater) in Australia (Parenteral) (Innovent Biologics pipeline, June 2024)
  • 18 Oct 2023 Innovent Biologics plans a first-in-human phase I/II trial in Multiple myeloma (Second line therapy or greater) in Australia (Parenteral) in February 2024 (NCT06083207)
  • 18 Oct 2023 IBI 3003 is available for licensing as of 18 Oct 2023. https://www.innoventbio.com/Collaborations/PartnerOfChoice#PartnerOfChoice

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top